The TREK dilatation catheter may be the delivery platform for Abbott’s future generations of stent technology. TREK is currently an investigational gadget and is not available for sale in america.. ADVENTRX holds Type A meeting with FDA to go over Exelbine NDA ADVENTRX Pharmaceuticals, Inc. announced today that it held a Type A meeting with the U.S. Culley, CEO of ADVENTRX. ‘The Agency’s assessment of the medical data gives us self-confidence a repeat study would be effective and that Exelbine can be approved.’ ‘Our money and equivalents of $40.7 million at July 31, plus cost benefits from discontinuing the Exelbine system, will provide us the capital to advance both our ANX-188 and ANX-514 programs to their respective pivotal scientific research next year.Results Study Individuals A complete of 299 patients in the usa , Canada , and Russia were randomly assigned to get a study drug at 70 investigative sites. The study began on December 5, 2005, and was completed on August 15, 2008. All individuals received at least 1 dose of research underwent and medication in least one safety evaluation after enrollment. Therefore, all sufferers were included in both intention-to-treat people and the safety population . As specified by the scholarly study protocol, the analysis drug was discontinued during the first breakthrough bout of hepatic encephalopathy.